RESUMO
Galactosyl-transferase KO (GalT-KO) pigs represent a potential solution to xenograft rejection, particularly in the context of additional genetic modifications. We have performed life supporting kidney xenotransplantation into baboons utilizing GalT-KO pigs transgenic for human CD55/CD59/CD39/HT. Baboons received tacrolimus, mycophenolate mofetil, corticosteroids and recombinant human C1 inhibitor combined with cyclophosphamide or bortezomib with or without 2-3 plasma exchanges. One baboon received a control GalT-KO xenograft with the latter immunosuppression. All immunosuppressed baboons rejected the xenografts between days 9 and 15 with signs of acute humoral rejection, in contrast to untreated controls (n = 2) that lost their grafts on days 3 and 4. Immunofluorescence analyses showed deposition of IgM, C3, C5b-9 in rejected grafts, without C4d staining, indicating classical complement pathway blockade but alternate pathway activation. Moreover, rejected organs exhibited predominantly monocyte/macrophage infiltration with minimal lymphocyte representation. None of the recipients showed any signs of porcine endogenous retrovirus transmission but some showed evidence of porcine cytomegalovirus (PCMV) replication within the xenografts. Our work indicates that the addition of bortezomib and plasma exchange to the immunosuppressive regimen did not significantly prolong the survival of multi-transgenic GalT-KO renal xenografts. Non-Gal antibodies, the alternative complement pathway, innate mechanisms with monocyte activation and PCMV replication may have contributed to rejection.
Assuntos
Ácidos Borônicos/uso terapêutico , Proteína Inibidora do Complemento C1/uso terapêutico , Galactosiltransferases/genética , Sobrevivência de Enxerto/fisiologia , Xenoenxertos , Transplante de Rim , Troca Plasmática , Pirazinas/uso terapêutico , Animais , Animais Geneticamente Modificados , Doenças Autoimunes , Bortezomib , Citomegalovirus/fisiologia , Galactosiltransferases/deficiência , Técnicas de Inativação de Genes , Imunidade Inata/fisiologia , Imunossupressores/uso terapêutico , Rim/cirurgia , Rim/virologia , Modelos Animais , Papio anubis , Sus scrofa , Replicação Viral/fisiologiaRESUMO
Differential protein glycosylation in the donor and recipient can have profound consequences for transplanted organs, as evident in ABO-incompatible transplantation and xenotransplantation. In this study, we investigated the impact of altered fucosylation on graft acceptance by using donor mice overexpressing human α1,2-fucosyltransferase (HTF). Skin and heart grafts from HTF transgenic mice were rapidly rejected by otherwise completely matched recipients (median survival times 16 and 14 days, respectively). HTF skin transplanted onto mice lacking T and B cells induced an natural killer cell-mediated innate rejection crisis that affected 50-95% of the graft at 10-20 days. However, in the absence of adaptive immunity, the residual graft recovered and survived long-term (>100 days). Experiments using "parked" grafts or MHC class II-deficient recipients suggested that indirect rather than direct antigen presentation plays a role in HTF skin graft rejection, although the putative antigen(s) was not identified. We conclude that altered glycosylation patterns on donor tissue can trigger a powerful rejection response comprising both innate and adaptive components. This has potential implications for allotransplantation, in light of increasing recognition of the variability of the human glycome, and for xenotransplantation, where carbohydrate remodeling has been a lynchpin of donor genetic modification.
Assuntos
Fucosiltransferases/metabolismo , Rejeição de Enxerto/etiologia , Transplante de Coração/efeitos adversos , Complexo Principal de Histocompatibilidade/fisiologia , Transplante de Pele/efeitos adversos , Transplante Heterólogo/efeitos adversos , Animais , Apresentação de Antígeno/imunologia , Feminino , Fucosiltransferases/genética , Glicosilação , Rejeição de Enxerto/mortalidade , Rejeição de Enxerto/patologia , Sobrevivência de Enxerto , Humanos , Técnicas Imunoenzimáticas , Células Matadoras Naturais/imunologia , Depleção Linfocítica , Masculino , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Prognóstico , Fatores de Risco , Taxa de Sobrevida , Linfócitos T/imunologia , Doadores de Tecidos , Transplante Homólogo , Galactosídeo 2-alfa-L-FucosiltransferaseRESUMO
The instant blood-mediated inflammatory reaction (IBMIR) is a major obstacle to the engraftment of intraportal pig islet xenografts in primates. Higher expression of the galactose-α1,3-galactose (αGal) xenoantigen on neonatal islet cell clusters (NICC) than on adult pig islets may provoke a stronger reaction, but this has not been tested in the baboon model. Here, we report that WT pig NICC xenografts triggered profound IBMIR in baboons, with intravascular clotting and graft destruction occurring within hours, which was not prevented by anti-thrombin treatment. In contrast, IBMIR was minimal when recipients were immunosuppressed with a clinically relevant protocol and transplanted with NICC from αGal-deficient pigs transgenic for the human complement regulators CD55 and CD59. These genetically modified (GM) NICC were less susceptible to humoral injury in vitro than WT NICC, inducing significantly less complement activation and thrombin generation when incubated with baboon platelet-poor plasma. Recipients of GM NICC developed a variable anti-pig antibody response, and examination of the grafts 1 month after transplant revealed significant cell-mediated rejection, although scattered insulin-positive cells were still present. Our results indicate that IBMIR can be attenuated in this model, but long-term graft survival may require more effective immunosuppression or further donor genetic modification.
Assuntos
Sangue , Rejeição de Enxerto , Transplante das Ilhotas Pancreáticas , Transplante Heterólogo , Animais , Anticorpos/sangue , Bovinos , PapioRESUMO
Thrombosis and inflammation are major obstacles to successful pig-to-human solid organ xenotransplantation. A potential solution is genetic modification of the donor pig to overexpress molecules such as the endothelial protein C receptor (EPCR), which has anticoagulant, anti-inflammatory and cytoprotective signaling properties. Transgenic mice expressing human EPCR (hEPCR) were generated and characterized to test this approach. hEPCR was expressed widely and its compatibility with the mouse protein C pathway was evident from the anticoagulant phenotype of the transgenic mice, which exhibited a prolonged tail bleeding time and resistance to collagen-induced thrombosis. hEPCR mice were protected in a model of warm renal ischemia reperfusion injury compared to wild type (WT) littermates (mean serum creatinine 39.0 ± 2.3 µmol/L vs. 78.5 ± 10.0 µmol/L, p < 0.05; mean injury score 31 ± 7% vs. 56 ± 5%, p < 0.05). Heterotopic cardiac xenografts from hEPCR mice showed a small but significant prolongation of survival in C6-deficient PVG rat recipients compared to WT grafts (median graft survival 6 vs. 5 days, p < 0.05), with less hemorrhage and edema in rejected transgenic grafts. These data indicate that it is possible to overexpress EPCR at a sufficient level to provide protection against transplant-related thrombotic and inflammatory injury, without detrimental effects in the donor animal.
Assuntos
Antígenos CD/metabolismo , Endotélio Vascular/metabolismo , Glicoproteínas/metabolismo , Modelos Animais , Receptores de Superfície Celular/metabolismo , Animais , Receptor de Proteína C Endotelial , Citometria de Fluxo , Humanos , Imuno-Histoquímica , Camundongos , Camundongos Transgênicos , Reação em Cadeia da Polimerase em Tempo Real , Traumatismo por Reperfusão/prevenção & controleRESUMO
Antioxidant enzymatic pathways form a critical network that detoxifies ROS in response to myocardial stress or injury. Genetic alteration of the expression levels of individual enzymes has yielded mixed results with regard to attenuating in vivo myocardial ischemia-reperfusion injury, an extreme oxidative stress. We hypothesized that overexpression of an antioxidant network (AON) composed of SOD1, SOD3, and glutathione peroxidase (GSHPx)-1 would reduce myocardial ischemia-reperfusion injury by limiting ROS-mediated lipid peroxidation and oxidative posttranslational modification (OPTM) of proteins. Both ex vivo and in vivo myocardial ischemia models were used to evaluate the effect of AON expression. After ischemia-reperfusion injury, infarct size was significantly reduced both ex vivo and in vivo, ROS formation, measured by dihydroethidium staining, was markedly decreased, ROS-mediated lipid peroxidation, measured by malondialdehyde production, was significantly limited, and OPTM of total myocardial proteins, including fatty acid-binding protein and sarco(endo)plasmic reticulum Ca(²+)-ATPase (SERCA)2a, was markedly reduced in AON mice, which overexpress SOD1, SOD3, and GSHPx-1, compared with wild-type mice. These data demonstrate that concomitant SOD1, SOD3, and GSHPX-1 expression confers marked protection against myocardial ischemia-reperfusion injury, reducing ROS, ROS-mediated lipid peroxidation, and OPTM of critical cardiac proteins, including cardiac fatty acid-binding protein and SERCA2a.
Assuntos
Antioxidantes/metabolismo , Traumatismo por Reperfusão Miocárdica/metabolismo , Miocárdio/metabolismo , Estresse Oxidativo/fisiologia , Processamento de Proteína Pós-Traducional/fisiologia , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/metabolismo , Animais , Glutationa Peroxidase/metabolismo , Peroxidação de Lipídeos/fisiologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Modelos Animais , Espécies Reativas de Oxigênio/metabolismo , Superóxido Dismutase/metabolismo , Superóxido Dismutase-1RESUMO
The ability of a hyperimmune Lew anti-BN serum (HIS) to induce enhancement of (Lew/BN)F1 kidneys transplanted into Lew recipients was compared to that of the same antiserum that had been depleted of hemagglutinating anti-Ag-B antibodies by absorption with Brown-Norway (BN) RBC-absorbed sera (RAS) or platelet-absorbed sera (PAS). The RAS and PAS were as effective as the unabsorbed HIS in abrogating early rejection as assessed by renal function and promotion of long-term survival. The absorbed sera retained the capacity to block the mixed lymphocyte culture (MLC) between Lew and BN lymphocytes and to a lesser degree the MLC between Lew and BUF, WF, AUG, and ACI lymphocytes; however, strain specificity was clearly evident at high antiserum dilutions. Similarly, these absorbed sera retained the capacity to block the Fc receptor of BN lymphocytes, and this effect was completely strain specific. In contrast, hemagglutinating and cytotoxic antibodies eluted from platelets used for antiserum absorption did not react with Fc receptors as assessed by rabbit antisheep (IgG)-coated SRBC (EA) rosette formation. F(Ab')2 fragments of PAS also blocked EA rosettes. On the other hand, complement rosettes (EAC) were not inhibited by the HIS. The antibodies were therefore directed against the Fc receptor itself or a structure spatially or functionally closely related to it. Both the Fc receptors and the enhancing capacity of the antisera were strictly specific for the BN genotype. It is suggested that the anti-"Fc receptor" antibody could play an important role in the induction of enhancement by impairing host T-B collaboration as a result of its binding to graft allogeneic "Fc receptors" which appear to be analogous to the major histocompatibility complex (MHC)-coded Ia antigens of the mouse.
Assuntos
Sítios de Ligação de Anticorpos , Antígenos HLA , Antígenos de Histocompatibilidade , Fragmentos Fc das Imunoglobulinas , Transplante de Rim , Imunologia de Transplantes , Animais , Especificidade de Anticorpos , Mapeamento Cromossômico , Proteínas do Sistema Complemento , Genótipo , Reação de Imunoaderência , Soros Imunes , Isoanticorpos , Teste de Cultura Mista de Linfócitos , Ratos , Ratos Endogâmicos BN/imunologia , Ratos Endogâmicos Lew/imunologia , Especificidade da Espécie , Transplante HomólogoRESUMO
The vascular ectonucleotidases CD39[ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), EC 3.6.1.5] and CD73[EC 3.1.3.5] generate adenosine from extracellular nucleotides. CD39 activity is critical in determining the response to ischemia-reperfusion injury (IRI), and CD39 null mice exhibit heightened sensitivity to renal IRI. Adenosine has multiple mechanisms of action in the vasculature including direct endothelial protection, antiinflammatory and antithrombotic effects and is protective in several models of IRI. Mice transgenic for human CD39 (hCD39) have increased capacity to generate adenosine. We therefore hypothesized that hCD39 transgenic mice would be protected from renal IRI. The overexpression of hCD39 conferred protection in a model of warm renal IRI, with reduced histological injury, less apoptosis and preserved serum creatinine and urea levels. Benefit was abrogated by pretreatment with an adenosine A2A receptor antagonist. Adoptive transfer experiments showed that expression of hCD39 on either the vasculature or circulating cells mitigated IRI. Furthermore, hCD39 transgenic kidneys transplanted into syngeneic recipients after prolonged cold storage performed significantly better and exhibited less histological injury than wild-type control grafts. Thus, systemic or local strategies to promote adenosine generation and signaling may have beneficial effects on warm and cold renal IRI, with implications for therapeutic application in clinical renal transplantation.
Assuntos
Antígenos CD/biossíntese , Apirase/biossíntese , Traumatismo por Reperfusão/prevenção & controle , Adenosina/metabolismo , Animais , Isquemia Fria , Humanos , Necrose do Córtex Renal/prevenção & controle , Camundongos , Camundongos Transgênicos , Modelos AnimaisRESUMO
Thrombomodulin (TBM) is an important vascular anticoagulant that has species specific effects. When expressed as a transgene in pigs, human (h)TBM might abrogate thrombotic manifestations of acute vascular rejection (AVR) that occur when GalT-KO and/or complement regulator transgenic pig organs are transplanted to primates. hTBM transgenic mice were generated and characterized to determine whether this approach might show benefit without the development of deleterious hemorrhagic phenotypes. hTBM mice are viable and are not subject to spontaneous hemorrhage, although they have a prolonged bleeding time. They are resistant to intravenous collagen-induced pulmonary thromboembolism, stasis-induced venous thrombosis and pulmonary embolism. Cardiac grafts from hTBM mice to rats treated with cyclosporine in a model of AVR have prolonged survival compared to controls. hTBM reduced the inflammatory reaction in the vein wall in the stasis-induced thrombosis and mouse-to-rat xenograft models and reduced HMGB1 levels in LPS-treated mice. These results indicate that transgenic expression of hTBM has anticoagulant and antiinflammatory effects that are graft-protective in murine models.
Assuntos
Anti-Inflamatórios/farmacologia , Ciclosporina/farmacologia , Animais , Modelos Animais de Doenças , Humanos , Camundongos , Camundongos Transgênicos , Ratos , Suínos , Trombomodulina , Transgenes/efeitos dos fármacosRESUMO
Incompatibility between pig thrombomodulin (TM) and primate thrombin is thought to be an important factor in the development of microvascular thrombosis in rejecting pig-to-primate xenografts. To examine this interaction at the molecular level, we cloned pig TM and measured its ability to bind human thrombin and act as a cofactor for the activation of human protein C and TAFI. The 579-residue pig TM protein showed approximately 69% sequence identity to human TM. Within the EGF domains necessary for binding of thrombin (EGF56), protein C (EGF4) and TAFI (EGF3), all of the amino acids previously identified as critical for the function of human TM, with the exception of Glu-408 in EGF5, were conserved in pig TM. Comparison of transfected cells expressing pig or human TM demonstrated that both proteins bound human thrombin and inhibited its procoagulant activity. However, pig TM was a poor cofactor for the activation of human protein C and TAFI, with domain swapping showing that EGF5 was the most important determinant of compatibility. Thus, while pig TM may be capable of binding thrombin generated in the vicinity of xenograft endothelium, its failure to promote the activation of human protein C remains a significant problem.
Assuntos
Proteína C/metabolismo , Trombina/metabolismo , Trombomodulina/metabolismo , Transplante Heterólogo/efeitos adversos , Animais , Carboxipeptidase B2/metabolismo , Coenzimas/metabolismo , Ativação Enzimática , Rejeição de Enxerto/metabolismo , Humanos , Microcirculação , Ligação Proteica , Suínos , Trombose/metabolismoRESUMO
We report herein the isolation and initial characterization of a novel protein, termed SP-40,40, which is present at moderate levels (35-105 micrograms/ml) in normal human serum. SP-40,40 is deposited in the renal glomeruli of patients with glomerulonephritis but is not found in normal glomeruli. The protein is a heterodimeric structure of relative molecular mass 80 kD, both chains of which are of a similar size (40 kD). The amino-terminal sequences of both chains are unrelated to one another and possess no significant homology to any known protein sequence. The tissue distribution of SP-40,40 closely resembles that of the terminal complement components and its physicochemical properties are similar to, but distinct from, those of the S protein of complement. We have identified SP-40,40 in the SC5b-9 complex of complement and have demonstrated incorporation of labeled SP-40,40 into this complex. These data suggest that SP-40,40 is an additional component of SC5b-9.
Assuntos
Proteínas Sanguíneas/análise , Proteínas Sanguíneas/isolamento & purificação , Complemento C5/análise , Glomerulonefrite/imunologia , Glomérulos Renais/análise , Chaperonas Moleculares , Sequência de Aminoácidos , Anticorpos Monoclonais/imunologia , Autorradiografia , Cromatografia em Gel , Cromatografia Líquida de Alta Pressão , Clusterina , Complemento C5b , Eletroforese em Gel de Ágar , Eletroforese em Gel de Poliacrilamida , Ensaio de Imunoadsorção Enzimática , Feminino , Glicoproteínas/análise , Humanos , Imunoensaio , Técnicas Imunoenzimáticas , Imuno-Histoquímica , Masculino , Dados de Sequência Molecular , Peso Molecular , VitronectinaRESUMO
RM2.184, a mouse IgG2a monoclonal antibody, recognizes a polymorphic determinant on the complement receptor for C3bi which is present on granulocytes and monocytes. The RM2.184 epitope is distinct from the monomorphic determinant recognized by the monoclonal antibody OKM1. The RM2.184 epitope is probably on the alpha subunit and dependent on the association of the alpha and beta subunits for its configuration, as it can not be detected after the subunits have been dissociated. The phenotypic frequency of the RM2.184 antigen is approximately 14%, and its segregation in families is independent of HLA and consistent with an autosomal co-dominant mode of inheritance.
Assuntos
Anticorpos Monoclonais , Receptores de Complemento/genética , Epitopos , Citometria de Fluxo , Imunofluorescência , Granulócitos/imunologia , Heterozigoto , Humanos , Monócitos/imunologia , Linhagem , Polimorfismo Genético , Conformação Proteica , Receptores de Complemento/imunologia , Receptores de Complemento 3b , Formação de RosetaRESUMO
Molecular cloning of the human complement inhibitor SP-40,40, has revealed strong homology to a major rat and ram Sertoli cell product, sulfated glycoprotein-2, known also as clusterin. This study reports the purification and characterization of human seminal clusterin. Two-dimensional gel electrophoresis revealed charge differences between clusterin purified from semen and the serum-derived material. Both preparations demonstrate comparable hemagglutination (clustering) activity and inhibition of C5b-6 initiated hemolysis. The average clusterin concentration in normal seminal plasma is considerably higher than that found in serum. Mean seminal plasma clusterin concentrations were significantly lower in azoospermia caused by obstruction or seminiferous tubule failure than with oligospermia or normospermia. Only men with vasal agenesis had undetectable seminal clusterin, suggesting that some of the seminal clusterin is produced by the seminal vesicles. Immunofluorescence of human spermatozoa revealed that clusterin was detected on 10% of spermatozoa, predominantly those that were immature or had abnormal morphology. A pilot study of 25 patients suggests that seminal clusterin concentration, together with sperm motility and morphology, is correlated with the fertilization rate in vitro. The function of seminal clusterin is unknown. Its extensive distribution in the male genital tract and its high concentration in seminal plasma suggests an important role in male fertility.
Assuntos
Glicoproteínas/isolamento & purificação , Chaperonas Moleculares , Sêmen/análise , Testículo/fisiologia , Animais , Cromatografia de Afinidade , Clusterina , Eletroforese em Gel Bidimensional , Ensaio de Imunoadsorção Enzimática , Feminino , Fertilização in vitro , Imunofluorescência , Glicoproteínas/sangue , Hemaglutinação , Humanos , Masculino , Peso Molecular , Ratos , Motilidade dos Espermatozoides , Espermatozoides/citologiaRESUMO
Islet transplantation can potentially cure type 1 diabetes mellitus, but it is limited by a shortage of human donors as well as by islet graft destruction by inflammatory and thrombotic mechanisms. A possible solution to these problems is to use genetically modified pig islets. Endothelial protein C receptor (EPCR) enhances protein C activation and regulates coagulation, inflammation, and apoptosis. We hypothesized that human EPCR (hEPCR) expression on donor islets would improve graft survival and function. Islets from an hEPCR transgenic mouse line strongly expressed the transgene, and hEPCR expression was maintained after islet isolation. Islets were transplanted from hEPCR mice and wild-type (WT) littermates into diabetic mice in a marginal-dose syngeneic intraportal islet transplantation model. The blood glucose level normalized within 5 days in 5 of 7 recipients of hEPCR islets, compared with only 2 of 7 recipients of WT islets (P < .05). Transplanted hEPCR islets had better preserved morphology and more intense insulin staining than WT grafts, and they retained transgene expression. The improved engraftment compared with WT islets suggests that inflammation and coagulation associated with the transplant process can be reduced by hEPCR expression on donor tissue.
Assuntos
Antígenos CD/metabolismo , Diabetes Mellitus Experimental/cirurgia , Diabetes Mellitus Tipo 1/cirurgia , Transplante das Ilhotas Pancreáticas , Receptores de Superfície Celular/metabolismo , Transplantes/metabolismo , Animais , Apoptose , Glicemia/análise , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Tipo 1/sangue , Receptor de Proteína C Endotelial , Sobrevivência de Enxerto , Humanos , Insulina/análise , Masculino , Camundongos , Camundongos Transgênicos , Substâncias Protetoras/metabolismo , Proteína C/metabolismo , SuínosRESUMO
Although originally generated to test the effect of eliminating the alpha-Gal epitope on HAR, it is becoming increasingly clear that GalT KO mice offer a convenient and inexpensive model to investigate many aspects of the anti-xenorgraft immune response. Clearly, not all aspects of anti-xenograft rejection responses are identical in mice and primates, which should be kept in mind when interpreting results of GalT KO mouse studies. However, with this and other mouse models it is possible to test a large number of variables, which is impractical for both logistical and financial reasons with primates. Furthermore the short gestation time and large litter size of mice means that genetic strategies targeting different aspects of the anti-xenograft immune response can be combined and subsequently tested to identify the optimal combination of genetic and therapeutic approaches to achieve long term xenograft survival. In this regard the GalT KO mouse has been and will continue to be a valuable small animal model for the study of all facets of xenograft rejection involving anti-Gal antibodies.
Assuntos
Galactosiltransferases/deficiência , Transplante Heterólogo/imunologia , Animais , Galactosiltransferases/genética , Camundongos , Camundongos KnockoutRESUMO
Over the past 20 years, the mortality and morbidity associated with cardiac allotransplantation has fallen significantly, providing a viable treatment for patients with terminal cardiac failure. Unfortunately, the increase in the number of patients who could benefit from cardiac transplantation has not been matched with an increase in the number of organs available for transplantation. Thus, many patients with cardiac failure die waiting for a suitable organ, unlike patients with renal failure, who can be maintained on dialysis while waiting for a kidney. Although the development of artificial hearts may provide a life-sustaining bridging therapy until a donor organ becomes available, the quality of life associated with cardiac prostheses is currently less than that following successful cardiac allotransplantation.
RESUMO
The activity of the transcription factor NF-kappaB is tightly regulated by the inhibitory molecule IkappaBalpha. Upon stimulation, IkappaBalpha is rapidly degraded and NF-kappaB translocates to the nucleus to induce gene expression. The IkappaBalpha degradation is preceded by phosphorylation, suggesting that this event plays a role in the activation of NF-kappaB. In this study, we have mutated three potential phosphorylation sites in porcine IkappaBalpha and found that expression of the Ser32 mutant of IkappaBalpha (IS32A), but not Tyr42 or Ser262 mutants or wild-type IkappaBalpha, blocked the activation of NF-kappaB by TNF-alpha. These results suggest that the Ser32 residue, a potential casein kinase II phosphorylation site, is critical for NF-kappaB activation.
Assuntos
NF-kappa B/antagonistas & inibidores , Proteínas Proto-Oncogênicas/química , Fatores de Transcrição , Animais , Caseína Quinase II , Genes Dominantes , Camundongos , Mutagênese Sítio-Dirigida , Fosforilação , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Proto-Oncogênicas/genética , Proteínas Recombinantes , Suínos , Fator de Transcrição RelB , Transcrição GênicaRESUMO
The liquid phase C1q-binding assay was used as a measure of circulating immune complexes in 147 renal transplant recipients. Thirty-six patients were studied serially from the time of transplantation. Abnormal levels of C1q-binding activity (C1qBA) were most frequently detected in the first 6 months post-transplant. Although there was a statistically significant association of elevated C1qBA with rejection, the incidence of "false positives" and "false negatives" was high and particularly evident in serial studies. There was no evidence of association between C1qBA and the recipients' original renal diseases. Post-transplant monitoring of renal transplant recipients for circulating immune complexes by the C1q-binding assay is an unreliable guide to rejection.
Assuntos
Complexo Antígeno-Anticorpo , Transplante de Rim , Enzimas Ativadoras do Complemento/análise , Enzimas Ativadoras do Complemento/metabolismo , Complemento C1q , Reações Falso-Negativas , Reações Falso-Positivas , Seguimentos , Rejeição de Enxerto , Humanos , Rim/metabolismo , Transplante HomólogoRESUMO
Monocyte cytotoxic crossmatches were performed on the sera of all 164 patients on the Victorian transplant waiting list in order to determine the incidence of antimonocyte antibodies and to assess if prospective screening for these antibodies would be justified. Initially all current sera were screened without absorption by the cytotoxicity assay for the presence of antilymphocyte and antimonocyte reactivity against a panel of ten donors. Subsequently, a further 45 "peak"-reactive sera were screened against the same panel. Forty sera with monocyte specific reactivity were selected. MHC class I and class II antibodies were absorbed with pooled platelets and B lymphoblastoid lines, respectively. The absorbed sera were then screened against T cells, B cells, and monocytes of 38 donors for monocyte-specific antibodies. Seven sera from six recipients showed monocyte reactivity without T cell or B cell reactivity, with panel reactivity ranging from 3-29%. This gives an overall patient incidence of 3.6%, and when expressed as a percentage of consecutive crossmatches has a calculated incidence of 0.45%. This incidence is much lower than previously reported and would indicate that prospective crossmatching for antimonocyte antibodies would not be of benefit in this group of patients.
Assuntos
Teste de Histocompatibilidade/métodos , Isoanticorpos/análise , Monócitos/imunologia , Linfócitos B/imunologia , Plaquetas/imunologia , Testes Imunológicos de Citotoxicidade , Humanos , Linfócitos/imunologiaRESUMO
BACKGROUND: It is now generally accepted that complement activation is critical for the hyperacute rejection of xenografts. Activation of the classical pathway as the result of the interaction of xenoreactive IgM xenoantibodies with the vascular endothelium has been observed in all species combinations examined to date. A number of studies using a variety of species combinations have also implicated alternate pathway involvement; however, these studies do not enable a conclusion to be drawn as to whether the alternate pathway can be activated in the complete absence of classical pathway activation. METHODS: In this study, human plasma was depleted of both Clq and factor D and then reconstituted with purified Clq or factor D to restore the classical and alternate complement pathways, respectively. The ability of these modified plasmas to prosecute hyperacute rejection was then examined using an ex vivo isolated mouse heart perfusion model based on the Langendorff system. RESULTS AND CONCLUSIONS: In the mouse to human species combination, both the classical and alternate pathways of complement are independently capable of initiating complement activation and mediating xenograft rejection.
Assuntos
Via Alternativa do Complemento/fisiologia , Via Clássica do Complemento/fisiologia , Rejeição de Enxerto/imunologia , Imunologia de Transplantes , Animais , Débito Cardíaco , Frequência Cardíaca , Humanos , Camundongos , Miocárdio , Transplante HeterólogoRESUMO
A murine monoclonal antihuman T cell antibody is described that is pan-T in that it reacts with all T cells, including those from thymus, but not with B cells or other cells, except for a small subpopulation of null cells. Biochemical analysis demonstrated that the antigen detected is a glycoprotein, Mr 50,000 daltons, in which sialic acid, alpha-fucose and alpha-mannose are the important terminal or subterminal carbohydrates. Further analysis indicated that the antigen is the E-rosette-forming-cell (ERFC) receptor or a closely associated structure. Three patients with renal allograft rejection were treated with the pan-T cell monoclonal antibody and, although the antibody was in excess and bound to circulating T cells, no lasting effect on T cell numbers or graft rejection was noted.